Non-viral gene therapy

https://doi.org/10.1016/0958-1669(94)90085-XGet rights and content

Abstract

Non-viral gene therapies are currently under development that employ drug-delivery methods for targeting genes to selected cells in the body, where they express therapeutic gene products. Various methods have been described for non-viral gene therapy, ranging from the direct intramuscular injection of purified DNA to the systemic administration of formulations comprising DNA and lipids, proteins, peptides, or polymers. Products for non-viral gene therapies are designed both for direct administration to patients by conventional routes and for expression of a therapeutic product over a finite period of time in a manner similar to conventional medicines. Initial preclinical and clinical studies indicate that non-viral gene delivery methods exhibit safety profiles similar to conventional pharmaceutical or biological products. Clinical trials have been proposed, or are currently under way, to assess the applicability of non-viral gene therapy for a variety of disorders, including cystic fibrosis, cancer, and peripheral vascular disease. Non-viral techniques may soon allow gene therapy to be applied in clinical practice alongside conventional medicines for the treatment of common diseases.

References (0)

Cited by (95)

  • Biomedical applications of carbon nanotubes with improved properties

    2018, Fullerenes, Graphenes and Nanotubes: A Pharmaceutical Approach
  • Carbon nanotubes: Applications in cancer therapy and drug delivery research

    2018, Emerging Nanotechnologies in Dentistry: Second Edition
  • Carbon Nanotubes: A Promising Carrier for Drug Delivery and Targeting

    2016, Nanoarchitectonics for Smart Delivery and Drug Targeting
  • Some approaches to large-scale manufacturing of liposomes

    2014, Emerging Nanotechnologies for Manufacturing
  • Carbon Nanotubes in Cancer Therapy and Drug Delivery

    2012, Emerging Nanotechnologies in Dentistry
View all citing articles on Scopus
View full text